This presentation may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements contain projections of Celsius Holdings’ future results of operations and/or financial position, or state other forward-looking information. In some cases you can identify these statements by forward-looking words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” “will,” “would,” or similar words. You should not rely on forward-looking statements since Celsius Holdings’ actual results may differ materially from those indicated by forward-looking statements as a result of a number of important factors. These factors include, but are not limited to: general economic and business conditions; our business strategy for expanding our presence in our industry; anticipated trends in our financial condition and results of operation; the impact of competition and technology change; existing and future regulations affecting our business; and other risks and uncertainties discussed in the reports Celsius Holdings has filed previously with the Securities and Exchange Commission. Celsius Holdings does not intend to and undertakes no duty to update the information contained in this presentation.

This document includes certain non-GAAP financial measures. Management considers GAAP financial measures as well as such non-GAAP financial information in its evaluation of the Company’s financial statements and believes these non-GAAP measures provide useful supplemental information to assess the Company’s operating performance and financial position. These measures should be viewed in addition to, and not in lieu of, the Company’s diluted earnings per share, operating performance and financial measures as calculated in accordance with GAAP.
Celsius Holdings, Inc. (Nasdaq: CELH), founded in April, 2004, is a global company, with a proprietary, clinically proven formula for flagship brand CELSIUS®.

Our mission - to become the global leader of a branded portfolio which is proprietary, clinically proven or innovative in its category, and offers significant health benefits.
PROVEN FUNCTIONAL ENERGY

BRAND ADDING CATEGORY VALUE
ATTRACTION MILLENNIAL AND
HEALTH CONCIOUS CONSUMERS

- THERMOGENIC
- ACCELERATES METABOLISM
- BURNS BODY FAT
- BURNS CALORIES
- PROVIDES HEALTHY ENERGY
- PROPRIETARY METAPLUS® BLEN

NO
- SUGAR
- HIGH FRUCTOSE CORN SYRUP
- ARTIFICIAL COLORS / FLAVORS
- ASPARTAME
- PRESERVATIVES
HOW DOES IT WORK?

CELSIUS® proprietary MetaPlus® formula, including green tea with EGCG, ginger and guarana seed, turns on thermogenesis, a process that boosts your body’s metabolic rate. ‡*

Drinking CELSIUS® prior to fitness activities is proven to energize, accelerate metabolism, burn body fat and calories. ‡*

*CELSIUS alone does not produce weight loss in the absence of a healthy diet and moderate exercise. In a 10 week clinical study published in the Journal of International Society of Sports Nutrition, with sedentary men and women, the group who drank one CELSIUS per day experienced Significantly Better Results.

†*These statements have not been evaluated by the Food & Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
CLINICAL STUDIES: PROVEN

STUDY 1 - OHIO RESEARCH:
PUBLISHED IN JOURNAL OF INTERNATIONAL SOCIETY OF SPORTS NUTRITION

STUDY 2 - UNIVERSITY OF OKLAHOMA:
PUBLISHED IN JOURNAL OF INTERNATIONAL SOCIETY OF SPORTS NUTRITION

STUDY 3 - UNIVERSITY OF OKLAHOMA:
PUBLISHED IN JOURNAL OF INTERNATIONAL SOCIETY OF SPORTS NUTRITION

STUDY 4 - UNIVERSITY OF OKLAHOMA:
PUBLISHED IN JOURNAL OF INTERNATIONAL SOCIETY OF SPORTS NUTRITION

STUDY 5 - UNIVERSITY OF OKLAHOMA:
PUBLISHED IN JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION

STUDY 6 - UNIVERSITY OF OKLAHOMA:
PUBLISHED IN THE JOURNAL OF STRENGTH AND CONDITIONING ASSOCIATION

STUDIES REVIEWED AND APPROVED BY THE NATIONAL ADVERTISING DIVISION (NAD) OF THE ADVERTISING SELF-REGULATORY COUNCIL
BEST FUNCTIONAL DRINK

WINNER

CELSIUS HEAT WINS "BEST PACKAGING DESIGN"

2018 INNOBEV GLOBAL SOFT DRINKS AWARDS
BY ZENITH

INNOBEV, GLOBAL AWARD WINNER
"BEST FUNCTIONAL DRINK 2017"

INNOVATION OF THE YEAR
BEVERAGE INDUSTRY
BEST IN ENERGY CATEGORY 2017

22 TIME AWARD WINNER

VARIOUS AWARDS AND ACHIEVEMENTS:
- BEST INNOVATION 2017
- BEST NEW PRODUCTS 2017
- BEST FUNCTIONAL DRINK
- INNOVATION IN BEVERAGE
- BEST SUPPLEMENTS AWARDS
- BETTER NUTRITION
- WORLD BEVERAGE INNOVATION AWARDS 2012
- FINALIST
- RETAILER CHOICE 2009
- BEVERAGE INNOVATION AWARDS 2011
- FINALIST
- BEST INNOVATION FOR FUNCTIONAL DRINKS 2010
- BEST INNOVATION 2008
- HIGHLY COMMENDED
- BEST NEW CATEGORY 2007
- BEVERAGE INDUSTRY
- BEST IN ENERGY CATEGORY 2017
CELIUS PIONEERS NEW GROUND
CLINICALLY PROVEN FUNCTION +
HEALTHY ENERGY
CELIUS is a proven Fitness Drink

CONSUMERS ARE READY FOR ENERGY 2.0
Sugary Energy Exit is NOW...
CELIUS is here

PIO NEERING POSITION: FITNESS DRINK

Masses are leaving artificial or sugary carbonated soft drinks and other categories in droves

CELIUS

CONVENTIONAL ENERGY
HEALTHIER ENERGY
HEALTHY, FUNCTIONAL, ENERGY
FUNCTIONAL
CELSIUS HEAT
POSITION: PERFORMANCE ENERGY

CELSIUS HEAT™ is a Carbonated, Proven To Perform, Thermogenic with METAPLUS®.

HEAT provides 100mg more caffeine than the original line, + 2,000mg L-Citruline.
Three year innovation pipeline built to reflect the following 3 categories:

- **BUILD THE CORE**: Build upon the current product lines with new flavor launches.
- **EXPANSION**: Expansion of products into adjacent categories.
- **DISRUPT THE MARKET**: Introduce new products to the marketplace.
Engage and inspire consumers to live an active healthy lifestyle and to partner with our brands for all facets of life!

Build brands consumers love in emerging on-trend categories to drive growth and shareholder value.
TOP SELLER ON AMAZON

“AMAZON’S CHOICE” WHEN SEARCHING
HEALTHY ENERGY (ORGANIC)

1,949+ LIFETIME REVIEWS, 4.3 STAR RATING

CELIUS was ahead of the curve with its relationship with Amazon. Our brand is on PRIME + Subscribe & Save.
CELSIUS BRAND PERFORMANCE VS. CATEGORY

CONVENIENCE CHANNEL

TOTAL SUB-CATEGORY
$8.6 BILLION

CATEGORY GROWTH +5.9%
200+ BRANDS

CELSIUS SIGNIFICANTLY OUTPACING CATEGORY GROWTH RATE
BRAND CELSIUS +36.5%
OUTPACING CATEGORY GROWTH 6.2x

RANKED 17TH TOP BRAND
WITH ONLY 10.2 ACV POINTS

LATEST 52 WEEKS ENDING 12.30.2018; SHELF STABLE FUNCTIONAL BEVERAGES; TPL; SPINSSCAN CONVENTIONAL MARKETS TOTAL US - CONVENIENCE
PLACEMENT: ENERGY, FUNCTIONAL

EACH CHANNEL HAS A DEFINED PLACEMENT STRATEGY.

CELSIUS® IS SOLD AMBIENT AND COLD ACROSS CHANNELS, IN GROCERY OR PHARMACY IN MULTIPACKS. IN FITNESS / EMERGING CHANNELS, COLD.
The original marketing mix (Product, Price, Place, and Promotion, or 4 Ps, as originally proposed by marketer and academic E. Jerome McCarthy (1960))
PROMOTION

THE MAKING OF AN ICON

TOUGHER MUGGER
INCREASING BRAND AWARENESS

• Tough Mudder – 23 cities, 161,000 attendees. 93% of attendees are sampled +15MM social media impressions

• Influencer Program: National reach to extend over 55MM followers and over 100MM impressions in 2019!

• Demos: Estimating to sample 175,000 consumers in 2019

• Media: Integrated targeted Digital and Social media campaigns
A Collective 80 MM followers and Over 130 MM impressions in 2019!

Priyanka Chopra – 102M Followers
Vanessa Hudgens – 53M Followers
Gary Vaynerchuck – 10.2M Followers
Erika Costell – 9.6M Followers
Howie Mandel – 4M Followers
Mario Lopez – 3.48M Followers

Inside, there is a large container of arugula, which she says she eats “almost every day,” cans of CELSIUS Sparkling Watermelon energy drink... “I love finding things that are good for you and also taste amazing,” she says.

Women’s Health Mag
37MM impressions
CONSUMER ADS – FITNESS TARGETS

ON TREND FOR PERFORMANCE ENERGY

HONING IN ON TARGET DEMO WITH KEY BRAND MESSAGING
Over 430,000 attendees across 30 shows delivering over 1.2MM impressions in 2019!

- 4 consumer-focused trade shows
  - The FitExpo LA
  - The Arnold Classic
  - IHRSA
  - Mr. Olympia

- 260,000+ attendees
- 150,000+ attendees will be sampled
- 800,000+ impressions

- 26 industry-focused Trade Shows
  - Europa Games
  - Expo West
  - NAMA
  - NACS

- 170,000+ attendees
- 45,000+ attendees to be sampled
- 410,000+ impressions
GLOBAL EXPANSION

NORDIC

CHINA

HONG KONG
PARTNERS WITH DEFINED TERRITORIES WHICH CURRENTLY PROVIDE MARKETING AND SALES SUPPORT WITHIN THEIR TERRITORY.

Established:
- Sweden - Top selling FITNESS drink in Sweden
- Finland expansion launched in 2016 adds incremental growth
- Norway launch announced February of 2018

Additional international opportunities with identified distribution partners
PARTNERS WITH DEFINED TERRITORIES WHICH CURRENTLY PROVIDE MARKETING AND SALES SUPPORT WITHIN THEIR TERRITORY.

Established:
- Hong Kong launched through A.S. Watson Water distributors in 2017
- China market launched with nationwide distribution through partnership with Qifeng Food Technology (Beijing) Co. Ltd., a national wholesale distributor of foods and beverages in 2017
- Effective January 1st 2019, a royalty license and repayment of investment agreement was established, creating a risk-mitigated method of capturing market share in China.

ADDITIONAL OPPORTUNITIES WITH IDENTIFIED DISTRIBUTION PARTNERS
STRATEGY OBJECTIVES AND GROWTH ROADMAP

TEAM VALUE
- FOCUSED
- DISCIPLINED
- RESULT ORIENTATED
- PURPOSE DRIVEN

SUPPLY CHAIN
- IMPROVE MARGINS
- DATA ANALYTICS
- OPERATIONAL FOCUS
- TRANSFORM FOR SCALE

BRAND BUILDING
- BUILD BRAND EQUITY
- INCREASE PORTFOLIO BREATH
- CHANNEL EXPANSION
- ACV GAINS

CELSIUS
 LIVE FIT
KEY TAKE AWAYS

- Resounding consumer demand - trend forward
- Rapidly growing revenues and gross profits
- Expanded product offering
- Innovative portfolio capitalizing on health & wellness trends
- Transforming operations for scale
- Disciplined data-driven team
GROWTH TRENDS IN REVENUE FULL COMPANY BY YEAR

Net Revenue by Year 2015-2018

- CAGR for 3 Years Total Company = >45%
GROWTH TRENDS IN REVENUE BY REGION

Net Revenue by Year 2015-2018

- Domestic CARG @ 64%
- International CARG @ 18%
- Strong Growth in the US => Capitalizing on Health & Wellness trends
- Driving penetration in all major market segments
Despite some seasonality & Intl orders, business reflects an overall continued growth.
GROSS PROFIT “NORMALIZATION” BY YEAR

- Large competitors such as Monster exclude Out-Bound Freight as part of Cost of Sales
- When “Normalized” on a comparable basis => Celsius Margins are north of 50%
BALANCE SHEET DASHBOARD - Working Capital Components

- **DSO = > 39 Days w/o International**
  - DSO (Daily Sales Outstanding)
  - Includes Bill Backs => To be Netted against Accrual

- **DOH = > 107 Days**
  - DOH (Days On Hand) Excludes E/O
  - Reflects “Build-Up” Strategy

- **DPO = > 57**
  - DPO (Days Payable Outstanding)
  - Affected by lower Q4 vol & Inv Build

- **Working Capital Turns ~4**
  - Inv build
### Adjusted EBITDA Computation

**For the twelve Months Ended Dec 31**

<table>
<thead>
<tr>
<th></th>
<th>Twelve months ended Dec 31,</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2018</td>
</tr>
<tr>
<td>Net income (loss) available to common stockholders (GAAP measure)</td>
<td>(11,419,781)</td>
</tr>
<tr>
<td><strong>Add back:</strong></td>
<td></td>
</tr>
<tr>
<td>Depreciation and amortization expense</td>
<td>51,205</td>
</tr>
<tr>
<td>Net interest expense</td>
<td>174,409</td>
</tr>
<tr>
<td>Preferred stock dividend</td>
<td>213,133</td>
</tr>
<tr>
<td>Stock-based compensation</td>
<td>4,293,797</td>
</tr>
<tr>
<td>Loss on Debt Extinguishment</td>
<td>377,048</td>
</tr>
<tr>
<td><strong>Non-GAAP Adjusted EBITDA</strong></td>
<td>(6,310,189)</td>
</tr>
<tr>
<td><strong>Non-recurring one-time charges:</strong></td>
<td></td>
</tr>
<tr>
<td>Inventory write-down, Priority Testing &amp; Label artwork change fees</td>
<td>183,042</td>
</tr>
<tr>
<td>Label artwork change fees</td>
<td>-</td>
</tr>
<tr>
<td>Recruiting fees</td>
<td>100,583</td>
</tr>
<tr>
<td>CEO retirement compensation</td>
<td>-</td>
</tr>
<tr>
<td>Legal settlement</td>
<td>1,019,600</td>
</tr>
<tr>
<td><strong>Total non-recurring one-time charges</strong></td>
<td>1,303,225</td>
</tr>
<tr>
<td><strong>Non-GAAP Adjusted EBITDA excluding one-time charges</strong></td>
<td>(5,006,964)</td>
</tr>
<tr>
<td>Net Asia investment</td>
<td>7,192,928</td>
</tr>
<tr>
<td><strong>Net Non-GAAP Adjusted EBITDA excluding net Asia investment</strong></td>
<td>2,185,964</td>
</tr>
</tbody>
</table>

- By excluding “Non-Cash” items and non-recurring “One Timers” & China Investment business is delivering positive Ebitda
Horizon Ventures: investment arm of Mr. Li Ka-Shing, Asia’s wealthiest individual. Assets include over 15,000 health & beauty retail locations

Former Founder and Chairman of ReXall Sundown Inc. which he built into the world’s leading nutritional supplement supplier, sold for $1.8 billion in 2000

Celebrity & business mogul (several companies), powerful brand builder & influencer
JOHN FIELDLY – PRESIDENT & CEO
John Fieldly joined Celsius in 2012 and brings extensive consumer goods and financial/operational experience with a track record of driving strong financial performance. Results Driven Executive with over 20 years of broad financial and operational experience with extensive consumer goods background. As Celsius Holdings CEO and former CFO, John has demonstrated a proven track record of driving strong business results and shareholder value. His expertise stems from a strong background in financial leadership and operational expertise with a focus on process and procurement improvement strategies to maximize resources to drive revenue and operational efficiencies. Prior to joining Celsius Holdings in 2012, Fieldly worked with Oragenics, Inc. (OGEN), the world leader in novel antibiotics against infectious disease and proprietary OTC probiotics, specifically designed to enhance oral health for humans and pets. There, Fieldly held responsibility over all aspects of Oragenic’s finance functions, including financial planning, public reporting requirements as well as optimizing operational efficiencies and implementing procurement strategies to maximize operations. Building upon his consumer and retailer experience, Mr. Fieldly has previously held leadership roles at Lebhar-Friedman – the B2B leading media and marketing company servicing the retail industry, foodservice, healthcare, and targeted consumer markets for more than 90 years. In that role, Fieldly was responsible for business planning, financial reporting, and overseeing financial operations. Fieldly began his career in retail within the food/drug/mass (FDM) channel through various leadership roles with the Eckerd Corporation. His work included sales training, merchandising, impulse sales strategy and quality control. Fieldly supported the acquisition to CVS in 2004. At the time, Eckerd had more than 2,800 stores nationwide. Mr. Fieldly is a Certified Public Accountant in Florida and a graduate of University of South Florida, where he earned his Bachelor of Science degree in Accounting.

EDWIN NERGON-CARBALLO - CFO
Edwin Negron-Carballo brings over 30 years of financial and operational experience to the organization. His background includes domestic and international experience with work in standardization and implementation of Six Sigma processes, in complex and dynamic environments. He is well versed in USGAAP and IFRS as a Certified Public Accountant and has significant experience in mergers and acquisitions. His impressive and extensive career spans decades of senior financial management experience in major companies such as: Concurrent Manufacturing Solutions, Sodexo, S.A., Tyco Healthcare-Latin America, Energizer Battery, Frito-Lay and K.P.M.G-Peat Marwick. He was also a Member of the Board of Directors of BAS, S.A., as well as being named as a Top 25 Hispanic Business Corporate Elite. Mr. Negron-Carballo earned an MBA from the John M. Olin School of Business at Washington University in St. Louis, Missouri, and prior, a Bachelor of Science Degree with a major in Accounting, from Louisiana State University in Baton Rouge, LA.

MATT KAHN - EXECUTIVE VP OF MARKETING
Matt Kahn brings over 20 years of marketing experience to CELSIUS as their EVP of Marketing. Having served a majority of his career in the beverage industry, Matt has worked for companies such as The Coca-Cola Co., Glacéau Vitaminwater®, Smartwater® and Heineken USA. From VP to CMO, Matt has held key marketing roles with each entity. His most recent title prior to joining CELSIUS in October of 2018 was that of VP, Marketing for Save-A-Lot Food Stores. Matt began his beverage career at Coca-Cola in 1998 and in 2003 he joined Glacéau. In his leadership roles at Glacéau, Matt’s invaluables foresight strongly contributed to Glacéau’s sale to The Coca-Cola Company for $4.1B. In 2007, Kahn served as VP, Marketing for Powerade; wherein he led the strategy to modify the formula to ION4 to differentiate it from Gatorade – thereby introducing Powerade zero – the first zero-calorie sports drink. This bold move gained Powerade 13 share points in 2.5 years. When Matt was VP, Marketing for Heineken, he managed a portfolio of five brands including Dos Equis, for which he led the development of a best-in-class video campaign featuring “The Most Interesting Man in the World,” garnering international appeal. Matt received his MBA from The University of North Carolina at Chapel Hill and bachelor’s degree in Business Administration from Washington University in St. Louis.

JON MCKILLOP – SENIOR VICE PRESIDENT OF SALES – NORTH AMERICA
Jon McKillop has been recently promoted to Senior Vice President of Sales for North America, joining the CELH Executive team. Previously McKillop served as Vice President of Sales for the company’s non-traditional channels of trade, to include Fitness, Military, Vending, Travel and Food Service. McKillop’s career has spanned over 15 years in beverage and consumer packaged goods in both traditional and non-traditional channels of trade. Prior to his arrival at Celsius on May 3, 2016, McKillop served in a variety of management roles at Glanbia Performance Nutrition, a leading company in the branded sports nutrition space, most recently as National Director of Sales for the organizations American Body Building brand. Before that, McKillop held management posts at large corporations Pepsi Americas, Core-Mark International and Keurig. He holds an undergraduate degree in Marketing from Southern Oregon University.
William H. Milmoe
CO-CHAIRMAN
- Finance and accounting
- President CDS International Holdings
- Financial career includes roles with: Price Waterhouse, General Cinema Corp, Pepsi, independent bottler

Kevin Harrington
DIRECTOR
- New product development
- TV show “Shark Tank” alumni
- Launched over 500 products
- “As seen on TV” infomercial pioneer

John Fieldly
DIRECTOR
- Celsius CEO and prior CFO
- Career includes roles with: Oragenics leader in novel antibiotics and proprietary OTC probiotics, Lebhar-Friedman leader in B2B publishing, Eckerd Corporation

Tony Lau
CO-CHAIRMAN
- Horizons Ventures
- Asian market expert
- IB professional, M&A

Nick Castaldo
DIRECTOR
- Consumer services business
- Chain restaurant, banking and retailing
- Equity Partner and member of the founding management team of Anthony’s Coal Fired Pizza

Thomas E. Lynch
DIRECTOR
- Insurance
- Banking
- Public official

Hal Kravitz
DIRECTOR
- Extensive CPG/Beverage career and experience across all business functions
- Chairman, Board of Directors
- Certified Management Group
- Former CEO AQUA Hydrate
- 30 Year career at the Coca-Cola Company, most recently, President, Glaceau Division
CELSIUS HOLDINGS, INC.

COMPANY CONTACTS

John Fieldly, CEO
Celsius Holdings, Inc.
561.276.2239
jfieldly@celsius.com

Edwin Negron, CFO
Celsius Holdings, Inc.
561.900.2351
enegron@celsius.com

INVESTOR RELATIONS

Cameron Donahue, Partner
Hayden IR
651.653.1854
cameron@haydenir.com

VISIT OUR NEW INVESTOR WEBSITE: CELSIUSHoldingsINC.COM
# Consolidated Statements of Operations

For the year ended December 31, 2018

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>$52,603,986</td>
<td>$36,164,064</td>
</tr>
<tr>
<td>Cost of revenue</td>
<td>31,543,608</td>
<td>20,733,387</td>
</tr>
<tr>
<td>Gross profit</td>
<td>21,060,378</td>
<td>15,430,677</td>
</tr>
<tr>
<td>Selling and marketing expenses</td>
<td>21,213,530</td>
<td>16,611,369</td>
</tr>
<tr>
<td>General and administrative expenses</td>
<td>10,487,592</td>
<td>6,899,275</td>
</tr>
<tr>
<td>Total operating expense</td>
<td>31,701,122</td>
<td>23,510,644</td>
</tr>
<tr>
<td>Loss from operations</td>
<td>(10,640,744)</td>
<td>(8,079,967)</td>
</tr>
<tr>
<td>Other Expense:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interest expense</td>
<td>(174,409)</td>
<td>(160,616)</td>
</tr>
<tr>
<td>Loss on Debt Extinguishment</td>
<td>(377,048)</td>
<td>-</td>
</tr>
<tr>
<td>Amortization of Discount on Notes Payable</td>
<td>(14,447)</td>
<td>-</td>
</tr>
<tr>
<td>Total Other Expense</td>
<td>(565,904)</td>
<td>(160,616)</td>
</tr>
<tr>
<td>Net Loss</td>
<td>(11,206,648)</td>
<td>(8,240,583)</td>
</tr>
<tr>
<td>Preferred stock dividend – other</td>
<td>(213,133)</td>
<td>(365,995)</td>
</tr>
<tr>
<td>Net Loss available to common stockholders</td>
<td>$(11,419,781)</td>
<td>$(8,606,578)</td>
</tr>
<tr>
<td>Weighted average shares outstanding</td>
<td>50,050,696</td>
<td>44,419,162</td>
</tr>
<tr>
<td>Loss per share, basic and diluted</td>
<td>$(0.23)</td>
<td>$(0.19)</td>
</tr>
</tbody>
</table>
## BALANCE SHEET

<table>
<thead>
<tr>
<th>ASSETS</th>
<th>December 31, 2018</th>
<th>December 31, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current assets:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash</td>
<td>$ 7,743,181</td>
<td>$ 14,186,624</td>
</tr>
<tr>
<td>Accounts receivable, net</td>
<td>12,980,396</td>
<td>6,375,658</td>
</tr>
<tr>
<td>Inventories, net</td>
<td>11,482,701</td>
<td>5,305,505</td>
</tr>
<tr>
<td>Prepaid expenses and other current assets</td>
<td>2,299,375</td>
<td>1,180,444</td>
</tr>
<tr>
<td><strong>Total current assets</strong></td>
<td>34,505,653</td>
<td>27,048,231</td>
</tr>
<tr>
<td>Property and equipment, net</td>
<td>121,854</td>
<td>62,642</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td>$ 34,627,507</td>
<td>$ 27,110,873</td>
</tr>
</tbody>
</table>

| LIABILITIES AND STOCKHOLDERS’ EQUITY | | |
| Current liabilities: | | |
| Accounts payable and accrued expenses | $ 14,845,211 | $ 6,311,824 |
| Accrued preferred dividend | - | 133,883 |
| Other current liabilities | 19,933 | 17,921 |
| **Total current liabilities** | 14,865,144 | 6,463,628 |
| Long-term liabilities: | | |
| Revolving line of credit-note payable-related party | 3,500,000 | 3,500,000 |
| Note payables-related party | 4,459,381 | - |
| **Total Liabilities** | 22,824,525 | 9,963,628 |
| Stockholders’ Equity: | | |
| Preferred Stock, $0.001 par value; 2,500,000 shares authorized, zero and 6,760 shares issued and outstanding at December 31, 2018 and December 31, 2017, respectively | - | 7 |
| Common stock, $0.001 par value; 75,000,000 shares authorized, 57,002,508 and 45,701,593 shares issued and outstanding at December 31, 2018 and December 31, 2017, respectively | 57,003 | 45,702 |
| Additional paid-in capital | 85,153,667 | 79,101,824 |
| Accumulated other comprehensive loss | (26,997) | (39,378) |
| Accumulated deficit | (73,380,691) | (61,960,910) |
| **Total Stockholders’ Equity** | 11,802,982 | 17,147,245 |
| **Total Liabilities and Stockholders’ Equity** | $ 34,627,507 | $ 27,110,873 |